



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61K 31/4745* (2006.01)
C07D 471/14 (2006.01) *A61P 25/28* (2006.01)
C07D 498/04 (2006.01)

(21) International Application Number:

PCT/IB2013/054570

(22) International Filing Date:

3 June 2013 (03.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/660,142 15 June 2012 (15.06.2012) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).(72) Inventors: **DOUNAY, Amy, B.**; 21 E. Caramillo Street,
Colorado Springs, Colorado 80907 (US). **TUTTLE, Jam-
ison, B.**; 5 Jefferson Street, Marblehead, Massachusetts
01945 (US). **VERHOEST, Patrick, R.**; 23 Calvin Road,
Newton, Massachusetts 02460 (US).(74) Agent: **OLSON, A., Dean**; Pfizer Inc., Eastern Point
Road, MS8260-2141, Groton, CT 06340 (US).(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: TRICYCLIC COMPOUNDS AS KAT II INHIBITORS



(I)

(57) Abstract: Compounds of Formula (I), wherein R¹, R², X¹, Y¹, Z¹, and Z² are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

